WEBVTT - Sir Bill Denny: Where do Daffodil Day donations go?

0:00:05.761 --> 0:00:09.961
<v Speaker 1>You're listening to the Weekend Collective podcast from News Talk SEDB.

0:00:34.241 --> 0:00:36.761
<v Speaker 2>And welcome back to the show. This is the Weekend

0:00:36.761 --> 0:00:39.521
<v Speaker 2>Collective and I'm Tim Beverage and this is the Health Hub.

0:00:39.561 --> 0:00:41.321
<v Speaker 2>We want your we'd love to have your cause on

0:00:41.321 --> 0:00:48.721
<v Speaker 2>this on ten eighteen text. But this health Hub is

0:00:48.761 --> 0:00:50.401
<v Speaker 2>a sort of bit of a special health hub because

0:00:50.481 --> 0:00:54.361
<v Speaker 2>August is well known as the Cancer Society's big fundraising month.

0:00:55.001 --> 0:00:56.961
<v Speaker 2>Again it's once again it's supported by A and Z

0:00:57.521 --> 0:01:01.121
<v Speaker 2>and Daffodil Day is well, it's it's not too far away.

0:01:01.121 --> 0:01:03.841
<v Speaker 2>It's Friday, the thirtieth of August. But you don't have

0:01:03.881 --> 0:01:06.681
<v Speaker 2>to wait till then. If you're in a position to

0:01:06.761 --> 0:01:09.201
<v Speaker 2>help the one in three Kiwis who are affected by cancer,

0:01:09.801 --> 0:01:13.401
<v Speaker 2>you can actually donate now. You can text the word

0:01:13.801 --> 0:01:18.081
<v Speaker 2>donate two two double four to two. Okay, so the

0:01:18.161 --> 0:01:19.881
<v Speaker 2>number is two double four to two. You text the

0:01:19.881 --> 0:01:22.241
<v Speaker 2>word donate and then what happens is you'll get a

0:01:22.281 --> 0:01:25.481
<v Speaker 2>link and you can select your donation amount and the

0:01:25.521 --> 0:01:29.401
<v Speaker 2>donations from Kiwi's help with research into all sorts of cancers.

0:01:29.721 --> 0:01:32.561
<v Speaker 2>And it's a Daffodil Day soon, so good time to

0:01:32.561 --> 0:01:34.521
<v Speaker 2>find a bit more about that research. So joining us

0:01:34.521 --> 0:01:37.121
<v Speaker 2>in the studio is a very special guest. He's a

0:01:37.161 --> 0:01:41.641
<v Speaker 2>past director of the Auckland Cancer Society Research Center. I'm

0:01:41.641 --> 0:01:43.401
<v Speaker 2>going to read a bit of his CV out. Then

0:01:43.401 --> 0:01:45.361
<v Speaker 2>we're going to dig into a bit more about Professor

0:01:45.401 --> 0:01:49.321
<v Speaker 2>Sibil Denny. But his interests include the design and evaluation

0:01:49.401 --> 0:01:51.881
<v Speaker 2>of small molecule drugs. He's been involved in the development

0:01:51.921 --> 0:01:55.081
<v Speaker 2>of fourteen drugs to clinical trial. He'll be embarrassed if

0:01:55.121 --> 0:01:56.761
<v Speaker 2>I read out as awards, but he's got a few.

0:01:57.241 --> 0:02:01.321
<v Speaker 2>He's serve build Any. For a start, he's received the

0:02:01.361 --> 0:02:04.041
<v Speaker 2>Rutherford Medal of the Royal Society of New Zealand, the

0:02:04.081 --> 0:02:07.081
<v Speaker 2>Adrian Albert Meda of the UK Royal Society of Chemistry,

0:02:07.121 --> 0:02:11.161
<v Speaker 2>in the twenty fourteen Medicinal Chemistry Award of the American

0:02:11.241 --> 0:02:16.801
<v Speaker 2>Chemical Society. Anyway, I think the gist is if you've

0:02:16.841 --> 0:02:19.361
<v Speaker 2>got some questions, or you're interested in the science and

0:02:19.361 --> 0:02:24.081
<v Speaker 2>the development of cancer cures and technology and research, then

0:02:24.161 --> 0:02:25.841
<v Speaker 2>this is the hour for you. So joining me in

0:02:25.881 --> 0:02:28.281
<v Speaker 2>the studios, Professor to bild Any, I'm just going to

0:02:28.361 --> 0:02:30.041
<v Speaker 2>call you Bill, good Bill, how are you.

0:02:30.561 --> 0:02:32.321
<v Speaker 3>I'm fine, that's the best way to do it.

0:02:32.401 --> 0:02:34.721
<v Speaker 2>Excellent. Firstly, just to find out a bit about you.

0:02:34.841 --> 0:02:36.601
<v Speaker 2>I mean, I did read out the awards because I

0:02:36.601 --> 0:02:38.641
<v Speaker 2>thought we should we should start by polishing your apple

0:02:38.641 --> 0:02:42.001
<v Speaker 2>a little bit. But how did you you have you've

0:02:42.001 --> 0:02:45.041
<v Speaker 2>recently retired and you've had a lengthy career. But how

0:02:45.761 --> 0:02:47.841
<v Speaker 2>did you get started in science full stop?

0:02:48.561 --> 0:02:48.721
<v Speaker 4>Well?

0:02:48.721 --> 0:02:51.361
<v Speaker 3>I got started in science because I was always interested

0:02:51.401 --> 0:02:54.241
<v Speaker 3>in chemistry for some particular reason, even when I was

0:02:54.441 --> 0:02:58.481
<v Speaker 3>a child, and I remember I collected my own group

0:02:58.561 --> 0:03:00.481
<v Speaker 3>of chemicals and I had to shed out the back

0:03:00.521 --> 0:03:06.401
<v Speaker 3>which I made explosions and various dangerous things. My parents

0:03:06.401 --> 0:03:12.201
<v Speaker 3>were very accepting of that, and I followed that right

0:03:12.241 --> 0:03:17.201
<v Speaker 3>through into into school and then into university and ended

0:03:17.281 --> 0:03:21.441
<v Speaker 3>up at the University of Oxford, where I spent three years.

0:03:22.281 --> 0:03:26.041
<v Speaker 3>And at that particular, at the end of that time,

0:03:26.081 --> 0:03:28.561
<v Speaker 3>we started to look around for jobs for me in

0:03:28.601 --> 0:03:31.641
<v Speaker 3>the UK, and I was expecting to go maybe into

0:03:31.641 --> 0:03:34.641
<v Speaker 3>a pharmaceutical company there, and then I got a call

0:03:34.721 --> 0:03:37.121
<v Speaker 3>from someone, and it was a letter in those days

0:03:37.801 --> 0:03:42.041
<v Speaker 3>from Bruce Kane, who was then director of the Auckland

0:03:42.081 --> 0:03:45.281
<v Speaker 3>Kancer Society Research Center, wanted to know if I would

0:03:45.361 --> 0:03:47.481
<v Speaker 3>like to come back and join the center.

0:03:47.961 --> 0:03:50.361
<v Speaker 2>So how did you go from sort of it sounds

0:03:50.401 --> 0:03:52.081
<v Speaker 2>like you're blowing things up in your shed, a little

0:03:52.121 --> 0:03:55.561
<v Speaker 2>bit like Sir Peter Beck, except you didn't go into rockets.

0:03:55.601 --> 0:03:58.881
<v Speaker 2>You went into into sort of medicinal chemistry. When when

0:03:58.881 --> 0:04:02.801
<v Speaker 2>did you When did your interest refine from you know,

0:04:02.841 --> 0:04:07.561
<v Speaker 2>your initial undergraduate studies of doing I'm guessing you did chemistry.

0:04:08.641 --> 0:04:12.761
<v Speaker 2>When did that refine into something that became useful for

0:04:13.801 --> 0:04:14.521
<v Speaker 2>medical research?

0:04:15.601 --> 0:04:15.721
<v Speaker 4>Well?

0:04:15.761 --> 0:04:18.921
<v Speaker 3>I thought I was interested in chemistry because of what

0:04:18.961 --> 0:04:21.281
<v Speaker 3>you can do with it and how you can develop

0:04:22.441 --> 0:04:27.121
<v Speaker 3>new molecules, and that was what I was doing in Oxford.

0:04:27.281 --> 0:04:29.841
<v Speaker 3>And when I got the I hadn't really thought about

0:04:30.041 --> 0:04:34.161
<v Speaker 3>cancer research until I got the letter from Bruce Kane

0:04:34.601 --> 0:04:36.881
<v Speaker 3>asking me would I like to join the Cancer Research

0:04:37.001 --> 0:04:40.041
<v Speaker 3>Center because they were developing new drugs therapy. How long

0:04:40.081 --> 0:04:45.721
<v Speaker 3>ago was that, Oh, nineteen sixty, I'm nineteen seventy something.

0:04:45.481 --> 0:04:46.321
<v Speaker 2>Like that, criky.

0:04:46.961 --> 0:04:49.961
<v Speaker 3>Yeah, it's been a long journey, but a very very

0:04:50.041 --> 0:04:50.801
<v Speaker 3>rewarding one.

0:04:50.921 --> 0:04:54.001
<v Speaker 2>And what was the state of cancer research and treatment

0:04:54.441 --> 0:04:55.801
<v Speaker 2>back when you started.

0:04:58.161 --> 0:05:00.961
<v Speaker 3>Well, it was a lot less effective than it is

0:05:01.041 --> 0:05:05.401
<v Speaker 3>now because in the last twenty thirty years, a lot

0:05:05.441 --> 0:05:08.841
<v Speaker 3>of work going on into developing drugs which are not

0:05:09.001 --> 0:05:13.561
<v Speaker 3>simply sell killing agents, but more or less this is

0:05:13.641 --> 0:05:17.961
<v Speaker 3>designed to select and treat specific cancers, so there's a

0:05:18.041 --> 0:05:20.921
<v Speaker 3>much more specificity now in the therapy.

0:05:21.641 --> 0:05:25.201
<v Speaker 2>What's the most It might be difficult to answer them

0:05:25.201 --> 0:05:28.001
<v Speaker 2>these questions because you've had such a lengthy career, but

0:05:28.361 --> 0:05:31.681
<v Speaker 2>is there anything that stands out to you through the

0:05:31.721 --> 0:05:35.081
<v Speaker 2>course of your career as being the most exciting sort

0:05:35.081 --> 0:05:38.121
<v Speaker 2>of development or the most a real moment where you've

0:05:38.121 --> 0:05:40.801
<v Speaker 2>got got where you've thought this is, this is this

0:05:40.921 --> 0:05:43.161
<v Speaker 2>is a real game changer when it comes to treating cancer.

0:05:44.881 --> 0:05:49.161
<v Speaker 3>It is a difficult question to answer, probably whenever we

0:05:49.441 --> 0:05:52.801
<v Speaker 3>succeed in getting a new drugs through into clinical trial,

0:05:53.521 --> 0:05:58.041
<v Speaker 3>probably because we've spent ten fifteen years working on refining

0:05:58.081 --> 0:06:00.481
<v Speaker 3>that to the stage where it has been accepted by

0:06:00.521 --> 0:06:03.961
<v Speaker 3>the authorities and can be used in Man. And for example,

0:06:04.401 --> 0:06:07.081
<v Speaker 3>we have now a drug and trial in Auckland Hospital

0:06:07.121 --> 0:06:13.881
<v Speaker 3>Tarlocksotten which has been developed by a couple of people

0:06:13.921 --> 0:06:16.041
<v Speaker 3>in the lab and that's taken them ten years to

0:06:16.081 --> 0:06:18.721
<v Speaker 3>get it to this point. So getting a drug over

0:06:18.761 --> 0:06:21.841
<v Speaker 3>the line the authority is accepted into even the first

0:06:21.881 --> 0:06:25.281
<v Speaker 3>stage trials is a big moment for everybody.

0:06:25.881 --> 0:06:29.601
<v Speaker 2>Uh, and what's that drug particularly, what's this, what's what's

0:06:29.641 --> 0:06:31.441
<v Speaker 2>that one about? What's the named treating.

0:06:32.841 --> 0:06:36.441
<v Speaker 3>We're still working that out. But the drugs drug is

0:06:36.441 --> 0:06:42.241
<v Speaker 3>one of a particular type which we call a it's

0:06:42.281 --> 0:06:45.121
<v Speaker 3>it's a pro drug in the sense that when you

0:06:45.121 --> 0:06:48.441
<v Speaker 3>give it cancer drug to people, the drug distributes everywhere

0:06:48.441 --> 0:06:51.481
<v Speaker 3>in the body and you end up with the side

0:06:51.521 --> 0:06:55.241
<v Speaker 3>effects that are inevitable from drug treatment because it doesn't

0:06:55.281 --> 0:06:58.521
<v Speaker 3>all it doesn't just go to the cancer. So with

0:06:58.761 --> 0:07:04.201
<v Speaker 3>this with tarsott is a pro drug which is circulates

0:07:04.321 --> 0:07:08.641
<v Speaker 3>all the around than the body, but it's relatively non

0:07:08.761 --> 0:07:11.561
<v Speaker 3>toxic and it's only when it gets into the low

0:07:11.601 --> 0:07:14.801
<v Speaker 3>oxygen regions of tumors that it turns itself on.

0:07:14.721 --> 0:07:18.481
<v Speaker 2>To be toxic. Okay, So in other words, from the

0:07:18.641 --> 0:07:21.881
<v Speaker 2>from the layperson's point of view, I've always under does

0:07:21.921 --> 0:07:24.121
<v Speaker 2>it still come under the headline of chemotherapy? Oh, it

0:07:24.161 --> 0:07:26.881
<v Speaker 2>is certainly that because chema. Well, actually, let's just so

0:07:26.961 --> 0:07:29.481
<v Speaker 2>people know, because chemotherapy in a way has a stigma

0:07:29.641 --> 0:07:33.161
<v Speaker 2>because you think you're up for chemotherapy. Therefore saygabidy, you'rre here,

0:07:33.241 --> 0:07:36.081
<v Speaker 2>sagabidy your health and hopefully the drug will just kill

0:07:36.121 --> 0:07:39.001
<v Speaker 2>your disease rather than you would be. Some people's fear

0:07:39.001 --> 0:07:44.121
<v Speaker 2>about chemotherapy, and is this one where it's more targeted? Well,

0:07:44.161 --> 0:07:46.121
<v Speaker 2>what is chemotherapy, I'll interrupt myself.

0:07:46.281 --> 0:07:49.561
<v Speaker 3>Human therapy is simply the treatment of cancer with small

0:07:49.641 --> 0:07:53.641
<v Speaker 3>molecular drugs. Okay, So, and as you say, those drugs

0:07:53.761 --> 0:07:58.281
<v Speaker 3>generally distribute everywhere in the body, and they do damage

0:07:58.321 --> 0:08:01.961
<v Speaker 3>to normal cells as well. I mean, perhaps still lesser extent,

0:08:02.161 --> 0:08:07.721
<v Speaker 3>but in the general course of events, you do get

0:08:07.761 --> 0:08:12.481
<v Speaker 3>side effects because the drug is distributed everywhere. It's killing

0:08:12.561 --> 0:08:20.401
<v Speaker 3>cancer cells, but there's also a concombatant cell kill in

0:08:20.641 --> 0:08:25.641
<v Speaker 3>various other areas in the body, especially where cells are

0:08:25.641 --> 0:08:26.641
<v Speaker 3>turning over rapidly.

0:08:27.401 --> 0:08:31.001
<v Speaker 2>That in a way would that be I'm going to

0:08:31.041 --> 0:08:32.801
<v Speaker 2>ask some dumb questions, by the way, because I'm not

0:08:32.841 --> 0:08:37.561
<v Speaker 2>a scientist, But to me, over the last few years,

0:08:37.681 --> 0:08:40.721
<v Speaker 2>I've got the impression that the treatments that are available

0:08:40.801 --> 0:08:44.801
<v Speaker 2>are more and more about just the drugs being smarter

0:08:45.081 --> 0:08:47.001
<v Speaker 2>and being able to what you're saying is a pro

0:08:47.161 --> 0:08:49.481
<v Speaker 2>what did you say pro so? In other words, so

0:08:49.521 --> 0:08:52.161
<v Speaker 2>it's not that's not just we're going to carpet bomb everything.

0:08:52.561 --> 0:08:54.921
<v Speaker 2>Now it's a bit more precision sort of targeting, and

0:08:55.321 --> 0:08:58.841
<v Speaker 2>is that maybe the biggest advance, one of the bigger

0:08:58.881 --> 0:09:00.201
<v Speaker 2>advances in chemotherapy.

0:09:00.841 --> 0:09:04.241
<v Speaker 3>There's two sorts of advances along the lines that you

0:09:04.281 --> 0:09:08.161
<v Speaker 3>say is we're developing molecules that are much more specific

0:09:08.361 --> 0:09:13.881
<v Speaker 3>for particular cancer types, and so that means we can

0:09:15.081 --> 0:09:18.401
<v Speaker 3>develop drugs to target cancer A or cancer B. And

0:09:19.081 --> 0:09:21.641
<v Speaker 3>it's a different drug. It's not simply we've got six

0:09:21.721 --> 0:09:25.001
<v Speaker 3>drugs and we give it to every patient. But the

0:09:25.041 --> 0:09:28.521
<v Speaker 3>other thing is, as we've said before, drugs, once they

0:09:28.561 --> 0:09:31.961
<v Speaker 3>get into the body distribute everywhere, and so the idea

0:09:31.961 --> 0:09:35.161
<v Speaker 3>of a pro drug is to have it inactive until

0:09:35.201 --> 0:09:40.401
<v Speaker 3>it enters the tumor cells. And we managed to do

0:09:40.441 --> 0:09:44.001
<v Speaker 3>that by recognizing that in tumors there is very low

0:09:44.041 --> 0:09:47.121
<v Speaker 3>oxygen levels. So if you can design a drug which

0:09:47.201 --> 0:09:51.001
<v Speaker 3>is not active in high oxygen levels but active in

0:09:51.041 --> 0:09:55.321
<v Speaker 3>low oxygen levels, then you will target cancer specifically. And

0:09:55.361 --> 0:09:58.161
<v Speaker 3>this is one of the major areas of interest in

0:09:58.201 --> 0:09:59.081
<v Speaker 3>our laboratory.

0:09:59.681 --> 0:10:04.561
<v Speaker 2>When so you talked about the colleagues who have developed this,

0:10:05.601 --> 0:10:08.201
<v Speaker 2>it's going to clinical trials. So clinical trials means it's

0:10:08.201 --> 0:10:10.641
<v Speaker 2>going to go into people. Is that right, that's correct.

0:10:10.681 --> 0:10:14.121
<v Speaker 3>There are three sorts of clinical trials. The first stage

0:10:14.161 --> 0:10:18.681
<v Speaker 3>one where you're simply evaluating the drug in people to

0:10:18.881 --> 0:10:22.121
<v Speaker 3>be concerned about toxicity efforts and things like that.

0:10:23.281 --> 0:10:25.041
<v Speaker 2>Yep. And what's stage two?

0:10:25.441 --> 0:10:31.121
<v Speaker 3>Stage two really is when you give the drug to

0:10:32.001 --> 0:10:34.761
<v Speaker 3>a larger number of people, but all with one specific

0:10:34.841 --> 0:10:38.561
<v Speaker 3>cancer type, so you can see whether this has general

0:10:38.601 --> 0:10:42.641
<v Speaker 3>effects beneficial effects in the cancer itself.

0:10:43.241 --> 0:10:46.681
<v Speaker 2>And stage three is three is what when it's basically

0:10:47.401 --> 0:10:49.201
<v Speaker 2>a larger proportion of people.

0:10:49.001 --> 0:10:52.881
<v Speaker 3>Or Stage three as rall is that it's a larger

0:10:52.921 --> 0:10:59.201
<v Speaker 3>proportion of people, usually around one thousand people, So you

0:10:59.241 --> 0:11:03.281
<v Speaker 3>want a broad spectrum of people with this particular disease

0:11:03.721 --> 0:11:06.521
<v Speaker 3>to see whether the drug is consistently effected.

0:11:06.641 --> 0:11:09.041
<v Speaker 2>And is that usually the stage where you're you're pretty

0:11:09.041 --> 0:11:11.081
<v Speaker 2>confident that it's a safe drug. You just want to

0:11:11.081 --> 0:11:13.241
<v Speaker 2>see how effective it is or is it still considering

0:11:13.281 --> 0:11:14.041
<v Speaker 2>issues of safety.

0:11:14.081 --> 0:11:17.961
<v Speaker 3>You've always been You've always got to consider issues of

0:11:18.001 --> 0:11:22.441
<v Speaker 3>safety because cancer drugs are generally designed to kill cells. Yeah,

0:11:22.641 --> 0:11:24.601
<v Speaker 3>and so with that, your safety has always got to

0:11:24.641 --> 0:11:25.641
<v Speaker 3>be a major concern.

0:11:26.121 --> 0:11:29.921
<v Speaker 2>Okay, So in the journey of from ten years from

0:11:30.321 --> 0:11:34.521
<v Speaker 2>developing a drug to going on clinical trials, what what

0:11:34.641 --> 0:11:37.361
<v Speaker 2>is the first year or two of that sort of

0:11:37.361 --> 0:11:42.001
<v Speaker 2>research look like, is it again dumb questions? But is

0:11:42.041 --> 0:11:43.721
<v Speaker 2>it sort of Petri dish sort of stuff?

0:11:43.881 --> 0:11:45.881
<v Speaker 3>Yeah, absolutely it is.

0:11:46.121 --> 0:11:46.681
<v Speaker 2>It's okay.

0:11:48.281 --> 0:11:51.681
<v Speaker 3>The chemist are in their lab devising all these interesting

0:11:51.761 --> 0:11:54.361
<v Speaker 3>new molecules that are new and they look exciting and

0:11:54.361 --> 0:11:57.201
<v Speaker 3>they're interesting to make. Then we test them all in cells,

0:11:57.361 --> 0:11:59.641
<v Speaker 3>just in cells and a petri dish, and most of

0:11:59.681 --> 0:12:02.241
<v Speaker 3>them fall over at that point, and.

0:12:02.641 --> 0:12:04.321
<v Speaker 2>Now they basically don't do what they've got. Do you

0:12:04.361 --> 0:12:06.601
<v Speaker 2>have some tumors or something you introduce a drug to

0:12:06.921 --> 0:12:08.801
<v Speaker 2>correct and you go, let's see what happens, and you know, oh,

0:12:08.841 --> 0:12:09.361
<v Speaker 2>that didn't work.

0:12:09.481 --> 0:12:12.321
<v Speaker 3>Yeah, that's right. I mean that's an awful lot of

0:12:12.361 --> 0:12:14.081
<v Speaker 3>what goes on in the lab. No, this didn't work.

0:12:14.121 --> 0:12:15.121
<v Speaker 3>Let's do something.

0:12:14.841 --> 0:12:17.641
<v Speaker 2>Else if you But just another dumb question. I'm going

0:12:17.681 --> 0:12:22.201
<v Speaker 2>to specialize in dumb questions. So when you are say,

0:12:22.321 --> 0:12:25.081
<v Speaker 2>you talk about having drugs that can thrive in a

0:12:25.121 --> 0:12:27.601
<v Speaker 2>low oxygen environment and that's those are the ones that

0:12:27.641 --> 0:12:31.281
<v Speaker 2>are going to target the cells. Does that mean what

0:12:31.441 --> 0:12:33.961
<v Speaker 2>sort of if you're doing it in a petri dish?

0:12:35.121 --> 0:12:37.201
<v Speaker 2>That sounds like it'd be quite a challenge because you

0:12:37.201 --> 0:12:39.921
<v Speaker 2>don't want to introduce oxygen at that stage either do

0:12:39.961 --> 0:12:41.761
<v Speaker 2>you you want it to have a low oxygen environment

0:12:42.001 --> 0:12:44.361
<v Speaker 2>in that peatra dish? So does that mean that the

0:12:44.361 --> 0:12:47.841
<v Speaker 2>equipment you've what does that mean in terms of equipment?

0:12:48.921 --> 0:12:50.961
<v Speaker 3>Or you can simply put the peachradish in a low

0:12:51.001 --> 0:12:51.961
<v Speaker 3>oxygen environment?

0:12:52.041 --> 0:12:53.681
<v Speaker 2>Yeah? What's a low oxygen environment?

0:12:54.201 --> 0:12:56.561
<v Speaker 3>Or oxygen levels below about one or two percent?

0:12:56.761 --> 0:12:56.841
<v Speaker 4>No?

0:12:56.881 --> 0:12:59.961
<v Speaker 2>I mean that is that just so? Is that in

0:13:00.001 --> 0:13:02.961
<v Speaker 2>a specific chamber or something stripped out of there?

0:13:03.481 --> 0:13:04.881
<v Speaker 3>We have the equipment to do that.

0:13:05.081 --> 0:13:09.441
<v Speaker 2>Yeah, okay, okay, before my brain needs a rest and

0:13:09.441 --> 0:13:11.281
<v Speaker 2>a cup of teaen to lie down, one more question

0:13:13.281 --> 0:13:14.801
<v Speaker 2>and we'll take your cause. By the way, if you've

0:13:14.841 --> 0:13:17.041
<v Speaker 2>got any questions around the science or if for professor

0:13:17.361 --> 0:13:20.121
<v Speaker 2>Sir Bill Denny, then this is your chance. Because we

0:13:20.281 --> 0:13:21.681
<v Speaker 2>a lot of the time when we do we talk

0:13:21.721 --> 0:13:24.041
<v Speaker 2>about health and cancer treatments and all sorts of things

0:13:24.081 --> 0:13:26.481
<v Speaker 2>on talkback. We don't have an expert in the room.

0:13:26.681 --> 0:13:28.521
<v Speaker 2>So we've got one and now so you can give

0:13:28.561 --> 0:13:30.041
<v Speaker 2>him a call. He's not a doctor, by the way,

0:13:30.041 --> 0:13:32.601
<v Speaker 2>in terms of a medical doctor. It's about the science

0:13:32.641 --> 0:13:36.401
<v Speaker 2>of developing molecules to treat cancers. If you've got any questions,

0:13:36.481 --> 0:13:38.521
<v Speaker 2>we'd love to hear from you. On eight hundred and

0:13:38.561 --> 0:13:40.561
<v Speaker 2>eighty ten eighty. By the way, I'm going to mention

0:13:40.641 --> 0:13:43.761
<v Speaker 2>it a few times probably, But if you want to

0:13:43.801 --> 0:13:47.641
<v Speaker 2>donate to for Daffodil Day, and it's thirtieth of August,

0:13:47.641 --> 0:13:50.601
<v Speaker 2>but rarely from now on, it's open. It's supported by

0:13:50.601 --> 0:13:52.761
<v Speaker 2>A and Z. All you need to do is text

0:13:52.841 --> 0:13:56.841
<v Speaker 2>the word donate to two four four two and there'll

0:13:56.841 --> 0:13:59.521
<v Speaker 2>be link you'll get and you can select your donation amount. Actually,

0:13:59.561 --> 0:14:01.441
<v Speaker 2>I'll come back with my interesting question about where we're

0:14:01.441 --> 0:14:03.961
<v Speaker 2>at in terms of New Zealand research in just a moment.

0:14:04.041 --> 0:14:06.161
<v Speaker 2>But this is the health up on the Weekend Collective.

0:14:06.641 --> 0:14:09.401
<v Speaker 2>It's twenty past four. News Talk said, b give us

0:14:09.401 --> 0:14:10.841
<v Speaker 2>a caller, you can text your question.

0:14:15.721 --> 0:14:20.841
<v Speaker 4>Don't show over, don't colder, don't stuck caring.

0:14:21.521 --> 0:14:27.001
<v Speaker 2>He mean welcome, you're not and welcome back to the

0:14:27.001 --> 0:14:29.801
<v Speaker 2>health Hub. I'm Tim Beverage and this is this is

0:14:29.841 --> 0:14:31.881
<v Speaker 2>a health hub looking forward to Daffodil Day on the

0:14:31.881 --> 0:14:34.281
<v Speaker 2>thirtieth of August. And my guess is Professor of Bill Denny.

0:14:34.481 --> 0:14:37.361
<v Speaker 2>He's former director of the Auckland Cancer Society Research Center

0:14:37.641 --> 0:14:41.361
<v Speaker 2>and we're just chatting basically about the scientific advancements when

0:14:41.401 --> 0:14:43.881
<v Speaker 2>it comes to treating cancers. But of course if you

0:14:43.921 --> 0:14:48.401
<v Speaker 2>want to support the work that has done to address

0:14:48.441 --> 0:14:52.121
<v Speaker 2>the challenge that cancer presents to right around New Zealand,

0:14:52.121 --> 0:14:54.241
<v Speaker 2>then you can text two four four two in the

0:14:54.241 --> 0:14:57.281
<v Speaker 2>word donate tense text donate to two four four two.

0:14:57.441 --> 0:15:00.521
<v Speaker 2>You'll get a link and you can select your donation amount. Bill.

0:15:01.241 --> 0:15:04.961
<v Speaker 2>How good are we in New Zealand at cancer research?

0:15:06.881 --> 0:15:09.601
<v Speaker 3>Well, I think we're very good, and I'm not speaking

0:15:10.241 --> 0:15:12.681
<v Speaker 3>just about our own research center, but there are groups

0:15:12.721 --> 0:15:15.081
<v Speaker 3>the Madigan Institute, there are groups in the University of

0:15:15.721 --> 0:15:19.881
<v Speaker 3>Otago which are carrying out a large number of which

0:15:19.921 --> 0:15:22.521
<v Speaker 3>are covering a large number of areas in cancer research,

0:15:22.801 --> 0:15:26.121
<v Speaker 3>which is a very broad area. So we've got in

0:15:26.161 --> 0:15:29.881
<v Speaker 3>most of the universities, we've got groups that are very

0:15:29.921 --> 0:15:36.641
<v Speaker 3>important and hooked up with groups overseas as well.

0:15:37.561 --> 0:15:39.481
<v Speaker 2>Has there been a big change in terms of science

0:15:39.521 --> 0:15:42.881
<v Speaker 2>ific research in our capabilities in New Zealand. So for instance,

0:15:43.401 --> 0:15:45.921
<v Speaker 2>I mean the analogy i'd use as everyone assumes that

0:15:45.921 --> 0:15:48.161
<v Speaker 2>everything a lot of the big advancements happen in Europe

0:15:48.201 --> 0:15:51.721
<v Speaker 2>or America. But of course now we've got on the

0:15:51.801 --> 0:15:54.641
<v Speaker 2>rocket science thing we've got. I mean, that's an obvious thing.

0:15:54.681 --> 0:15:58.601
<v Speaker 2>But does that reflect generally the science community in New

0:15:58.681 --> 0:16:01.161
<v Speaker 2>Zealand that actually, you know what, we are punching well

0:16:01.201 --> 0:16:01.881
<v Speaker 2>above our weight.

0:16:03.361 --> 0:16:05.641
<v Speaker 3>I think it's fair to say that very hard to

0:16:06.041 --> 0:16:09.241
<v Speaker 3>it's very hard to evaluate. We can't evaluate ourselves easily

0:16:09.321 --> 0:16:13.121
<v Speaker 3>against the United States, for example, because we're very small

0:16:13.161 --> 0:16:17.481
<v Speaker 3>and they're very big, but we have a presence there certainly.

0:16:17.801 --> 0:16:21.881
<v Speaker 2>Yeah, are there what are the things that I mean,

0:16:21.921 --> 0:16:23.601
<v Speaker 2>I don't know if you can talk about the research

0:16:23.641 --> 0:16:25.961
<v Speaker 2>that you're most excited about now, because I know a

0:16:26.001 --> 0:16:28.681
<v Speaker 2>lot of it's technical. But are there particular developments going

0:16:28.721 --> 0:16:32.521
<v Speaker 2>on now which you think, Wow, this is really pretty

0:16:32.521 --> 0:16:34.521
<v Speaker 2>amazing or is it just every time a drug comes

0:16:34.521 --> 0:16:37.041
<v Speaker 2>to trial you go, there's another victory that's exciting.

0:16:39.121 --> 0:16:43.601
<v Speaker 3>I think the research is much more targeted now because

0:16:43.601 --> 0:16:46.801
<v Speaker 3>we know so much more about the myriad enzymes that

0:16:46.841 --> 0:16:52.681
<v Speaker 3>are present in cells which sometimes go crazy, and we

0:16:52.721 --> 0:16:56.441
<v Speaker 3>can target them much more specifically. For example, there are

0:16:56.801 --> 0:17:01.521
<v Speaker 3>about one hundred different kinase enzymes and there are people

0:17:01.561 --> 0:17:05.161
<v Speaker 3>developing drugs specifically for each one of those. So I

0:17:05.201 --> 0:17:07.961
<v Speaker 3>think in future the drugs will even will be even

0:17:08.041 --> 0:17:10.881
<v Speaker 3>better targeted than they are. Now we've made a big

0:17:10.921 --> 0:17:13.641
<v Speaker 3>advance in that already are there.

0:17:14.721 --> 0:17:19.161
<v Speaker 2>While you're becoming more targeted with the drugs that you're creating,

0:17:19.721 --> 0:17:23.481
<v Speaker 2>does that mean that each drug you're creating treats fewer

0:17:23.561 --> 0:17:26.521
<v Speaker 2>cancers though they're more specific to each type of cancer.

0:17:27.121 --> 0:17:31.401
<v Speaker 2>So if you're a cancer suffering, you've got to again

0:17:31.521 --> 0:17:36.961
<v Speaker 2>dumb questions. So chemotherapy seemed to me, in my lay understanding,

0:17:36.961 --> 0:17:39.081
<v Speaker 2>to be something that was more broadly. You might have

0:17:39.081 --> 0:17:42.401
<v Speaker 2>one chemotherapy that would targets several different cancers. I don't know,

0:17:42.841 --> 0:17:46.281
<v Speaker 2>But now you've got this particular chemotherapy which is targeted

0:17:46.321 --> 0:17:48.161
<v Speaker 2>for this particular cancer. That's your drug.

0:17:49.241 --> 0:17:51.401
<v Speaker 3>We're going down that line. I mean, that is exactly

0:17:51.481 --> 0:17:55.201
<v Speaker 3>the area in which is being developed most vigously at

0:17:55.201 --> 0:17:57.521
<v Speaker 3>the moment. There's a large number of new drugs are

0:17:57.561 --> 0:18:01.721
<v Speaker 3>coming out. They're very specific for particular cell types, they're

0:18:01.801 --> 0:18:07.001
<v Speaker 3>very specific for particular enzymes, and so speaking, now it's

0:18:07.121 --> 0:18:11.241
<v Speaker 3>much easier to rapidly determine which enzymes in a particular

0:18:11.761 --> 0:18:16.681
<v Speaker 3>cancer has gone haywire and select the drugs that can

0:18:16.721 --> 0:18:20.041
<v Speaker 3>treat that. So treatment is much more selective much more

0:18:20.081 --> 0:18:22.601
<v Speaker 3>patient selective than it than it was before.

0:18:23.001 --> 0:18:26.961
<v Speaker 2>Okay, how do you how do you fund your research?

0:18:27.241 --> 0:18:28.681
<v Speaker 2>How do you get the money for it? Is it

0:18:28.961 --> 0:18:30.961
<v Speaker 2>things like Daffidilt Day? Where does the money come from?

0:18:32.081 --> 0:18:36.921
<v Speaker 3>Certainly the Cancer Society Auckland Cancer Society has set up

0:18:36.961 --> 0:18:41.361
<v Speaker 3>the center in the first place and has always been

0:18:41.401 --> 0:18:45.081
<v Speaker 3>a significant funder of it. But we also raise our

0:18:45.121 --> 0:18:51.321
<v Speaker 3>own funding through writing, writing grants for applications, and in

0:18:51.401 --> 0:18:55.601
<v Speaker 3>particular we've also had close relationships with several big pharmaceutical

0:18:55.641 --> 0:18:59.601
<v Speaker 3>companies who've been interested in the particular compounds we're developing,

0:19:00.001 --> 0:19:02.521
<v Speaker 3>and we've had a good support from them as well.

0:19:02.601 --> 0:19:07.161
<v Speaker 3>So we have a range of support from different areas.

0:19:07.361 --> 0:19:10.561
<v Speaker 2>What role does do What role does the charitable side

0:19:10.961 --> 0:19:16.561
<v Speaker 2>play when it comes to initiatives like Daffodil Day? How

0:19:16.601 --> 0:19:20.601
<v Speaker 2>important is the biggest thing about the money you raise

0:19:20.761 --> 0:19:22.761
<v Speaker 2>or is it more the awareness or is it a

0:19:22.801 --> 0:19:24.721
<v Speaker 2>package of the whole lot? In terms of this, what

0:19:24.841 --> 0:19:28.241
<v Speaker 2>daffodil Daffodil Day means well, deafit to.

0:19:28.281 --> 0:19:30.961
<v Speaker 3>Day is critical for the cancer societies because they do

0:19:31.081 --> 0:19:34.041
<v Speaker 3>lots of things other than just support our center. They

0:19:34.121 --> 0:19:37.961
<v Speaker 3>also run the main lodge here in Auckland where patients

0:19:37.961 --> 0:19:42.921
<v Speaker 3>who are receiving treatment can get free board, and they

0:19:44.081 --> 0:19:48.521
<v Speaker 3>support a fleet of nurses who go around to treat

0:19:48.521 --> 0:19:52.801
<v Speaker 3>people at home with follow up therapy. So there's a

0:19:52.801 --> 0:19:55.401
<v Speaker 3>lot of things that they do in a part apart

0:19:55.561 --> 0:19:58.761
<v Speaker 3>from partially funding the center.

0:19:59.321 --> 0:20:02.521
<v Speaker 2>Does the treatment of cancers mean that also that cancers

0:20:02.521 --> 0:20:05.001
<v Speaker 2>can more cancers can be treated. I mean, I don't know.

0:20:05.121 --> 0:20:06.881
<v Speaker 2>We still do we still have the four stage model

0:20:06.921 --> 0:20:10.801
<v Speaker 2>of cancer one stage one, two, three, and four, And

0:20:11.121 --> 0:20:14.401
<v Speaker 2>does it are we able to treat cancers later effectively?

0:20:16.881 --> 0:20:19.401
<v Speaker 3>That's getting a little bit outside my expertise, but my

0:20:20.201 --> 0:20:23.121
<v Speaker 3>sense is that that is certainly true. The drugs with it,

0:20:23.361 --> 0:20:27.601
<v Speaker 3>there are more drugs, they're more specific to particular targets,

0:20:28.081 --> 0:20:31.641
<v Speaker 3>and so you could if you can combine a number

0:20:31.681 --> 0:20:36.921
<v Speaker 3>of drugs to best target a particular cancer in a patience,

0:20:37.081 --> 0:20:39.801
<v Speaker 3>then that is that is an advance.

0:20:40.041 --> 0:20:42.641
<v Speaker 2>Yeah. I've got a few texts here which may or

0:20:42.681 --> 0:20:46.081
<v Speaker 2>maybe either in or outside of your area of expertise,

0:20:46.161 --> 0:20:53.281
<v Speaker 2>because when people hear doctor sud BUILDINGI, they think that

0:20:53.681 --> 0:20:55.521
<v Speaker 2>they think that maybe you're going to give them a

0:20:55.561 --> 0:20:58.241
<v Speaker 2>diagnosis on And I'll point out to anyone who's texting

0:20:58.241 --> 0:21:00.161
<v Speaker 2>that we I'll read some of the texts and if

0:21:00.161 --> 0:21:02.721
<v Speaker 2>we can answer them, sure, then then maybe some threat

0:21:02.761 --> 0:21:06.561
<v Speaker 2>of conversation will come out of them. So brace yourself. Okay, Oh,

0:21:06.601 --> 0:21:10.401
<v Speaker 2>this one's just an observation. Relates to my previous comment.

0:21:10.681 --> 0:21:12.721
<v Speaker 2>I have a friend who has stage four cancer. I

0:21:12.761 --> 0:21:15.121
<v Speaker 2>believe that used to be pretty much that much a

0:21:15.201 --> 0:21:18.361
<v Speaker 2>death sentence. But how times have changed and medicine has

0:21:18.401 --> 0:21:21.121
<v Speaker 2>improved that you can survive that level of cancer. And

0:21:21.121 --> 0:21:23.321
<v Speaker 2>that's sort of what we're saying. Isn't it even a

0:21:23.361 --> 0:21:24.081
<v Speaker 2>stage four cancer?

0:21:24.121 --> 0:21:27.081
<v Speaker 3>I would agree with that. Yeah, I think across the

0:21:27.801 --> 0:21:33.041
<v Speaker 3>spectrum there are more and better drugs that are more selective.

0:21:33.801 --> 0:21:37.521
<v Speaker 3>Although there's a limit to how many drugs can be

0:21:37.601 --> 0:21:42.001
<v Speaker 3>funded obviously, but looking at the field as a whole,

0:21:42.241 --> 0:21:44.681
<v Speaker 3>we're better off now than we've ever been in terms

0:21:44.681 --> 0:21:46.761
<v Speaker 3>of a bib ability to treat the disease.

0:21:47.081 --> 0:21:49.121
<v Speaker 2>Do you think what you get to a stage? Again?

0:21:49.281 --> 0:21:53.481
<v Speaker 2>I know you probably won't like guesswork because you're a scientist. Actually, okay,

0:21:53.521 --> 0:21:56.041
<v Speaker 2>I'm going to ask a dumb question. How much when

0:21:56.041 --> 0:22:00.681
<v Speaker 2>it comes to establishing a clinical trial is a scientist

0:22:00.721 --> 0:22:03.041
<v Speaker 2>going I see this works here, this has worked, This

0:22:03.081 --> 0:22:05.841
<v Speaker 2>has been an installary research, and it's pretty much you

0:22:05.921 --> 0:22:07.881
<v Speaker 2>just switch on that creative part of your brain. I

0:22:07.961 --> 0:22:12.401
<v Speaker 2>wonder if that drug might work here. In other words,

0:22:12.681 --> 0:22:16.081
<v Speaker 2>in the early stages, how much guesswork is there as

0:22:16.081 --> 0:22:19.721
<v Speaker 2>opposed to just evidence, evidence, evidence evidence. Therefore, we're going

0:22:19.801 --> 0:22:22.041
<v Speaker 2>to do this next. Do you know what I mean?

0:22:22.121 --> 0:22:24.161
<v Speaker 3>I think there's a lot of guesswork. Oh, I think

0:22:24.201 --> 0:22:27.201
<v Speaker 3>you have to have you have to have guesswork inspired

0:22:27.241 --> 0:22:29.081
<v Speaker 3>guess work is the basis of science.

0:22:29.401 --> 0:22:31.881
<v Speaker 2>Well, well, it's because let's try this that doesn't work,

0:22:32.001 --> 0:22:34.921
<v Speaker 2>and therefore that doesn't work. Okay, so oh good, because

0:22:34.961 --> 0:22:36.641
<v Speaker 2>I was relieved. That was one of my dumb questions.

0:22:36.681 --> 0:22:40.561
<v Speaker 3>Again, No, it's that's that's the essence of science.

0:22:40.761 --> 0:22:43.801
<v Speaker 2>Well, because this is a slightly broader question. But where

0:22:43.841 --> 0:22:47.841
<v Speaker 2>I was chatting with we're talking about career choices with kids,

0:22:47.841 --> 0:22:50.081
<v Speaker 2>and and there was a comment made I think it

0:22:50.161 --> 0:22:52.241
<v Speaker 2>was I'm not going to get involved in politics, don't

0:22:52.241 --> 0:22:55.681
<v Speaker 2>worry that. There was a comment made about from our

0:22:55.681 --> 0:22:57.601
<v Speaker 2>prime minister that the arts might need to take a

0:22:57.601 --> 0:23:00.081
<v Speaker 2>bit of a back seat, and I was thinking, well,

0:23:00.081 --> 0:23:02.081
<v Speaker 2>hang on a minute. Even some of our greatest scientific

0:23:02.161 --> 0:23:05.241
<v Speaker 2>minds have a creative bent. Because you have to have

0:23:05.801 --> 0:23:09.441
<v Speaker 2>those creative moments where you think were you're thinking outside

0:23:09.441 --> 0:23:11.321
<v Speaker 2>the box. In fact, science has to be thinking outside

0:23:11.361 --> 0:23:12.801
<v Speaker 2>the box all the time, isn't it right?

0:23:12.921 --> 0:23:15.521
<v Speaker 3>Absolutely, that's where the great changes come from.

0:23:15.601 --> 0:23:19.921
<v Speaker 2>Oh god, that's a relief to Okay, this is a

0:23:19.921 --> 0:23:21.761
<v Speaker 2>specific one. I'm not sure if you've able to help,

0:23:21.801 --> 0:23:23.881
<v Speaker 2>but I'll read it anyway. Hi, thank you for your time.

0:23:23.921 --> 0:23:27.441
<v Speaker 2>What further research are you aware of any research that's

0:23:27.481 --> 0:23:31.881
<v Speaker 2>been done with pre existing vulva liken slerosis and high

0:23:31.921 --> 0:23:36.641
<v Speaker 2>time risk of vulver cancer with this autoimmune disease? How

0:23:36.681 --> 0:23:39.081
<v Speaker 2>common is that cancer and is there any research going

0:23:39.121 --> 0:23:40.081
<v Speaker 2>into it that you know about.

0:23:41.521 --> 0:23:45.081
<v Speaker 3>I don't know of that cancer, which seems to me

0:23:45.161 --> 0:23:49.041
<v Speaker 3>to be relatively rare. Therefore, I really don't know what

0:23:49.081 --> 0:23:52.441
<v Speaker 3>research is going into that specific area. I'm sorry, I can't.

0:23:52.241 --> 0:23:55.121
<v Speaker 2>No, that's all right. What about prostate cancer? Do you

0:23:55.161 --> 0:23:58.641
<v Speaker 2>know much about what's going on with because that because

0:23:58.641 --> 0:24:01.481
<v Speaker 2>there's the big debate that you people say, oh, well,

0:24:01.561 --> 0:24:04.561
<v Speaker 2>you're better you die with prostate cancer than treat it,

0:24:04.601 --> 0:24:06.241
<v Speaker 2>and is the care you are better? Are there any

0:24:06.481 --> 0:24:09.281
<v Speaker 2>anything particular in prostate cancer that's going on right now?

0:24:09.721 --> 0:24:14.881
<v Speaker 3>Look? I don't specifically know of unique treatments for prostate cancer.

0:24:14.921 --> 0:24:18.401
<v Speaker 3>I mean, I can't really answer that question.

0:24:18.681 --> 0:24:21.921
<v Speaker 2>Yeah, okay, here's one about just thought of a good question,

0:24:24.441 --> 0:24:29.681
<v Speaker 2>specific drugs coming out, Will we see them or will

0:24:29.681 --> 0:24:33.161
<v Speaker 2>they be out of reach of New Zealanders because of pricing?

0:24:33.241 --> 0:24:37.881
<v Speaker 2>And I guess that's in asure around farmac. But any

0:24:37.881 --> 0:24:39.121
<v Speaker 2>comment on that, well.

0:24:38.961 --> 0:24:42.881
<v Speaker 3>The only comment is that the more drugs that are

0:24:42.921 --> 0:24:47.321
<v Speaker 3>collectively developed wherever they're developed, that are more and more specific,

0:24:48.321 --> 0:24:51.721
<v Speaker 3>the better it is for everybody. The question of whether

0:24:51.761 --> 0:24:54.601
<v Speaker 3>we can afford it is really a completely different question,

0:24:55.441 --> 0:24:59.441
<v Speaker 3>and we would I mean, obviously we prefer to have

0:24:59.761 --> 0:25:08.401
<v Speaker 3>a vigorous research area. Yeah, that is exploring everything. Yeah,

0:25:08.481 --> 0:25:10.801
<v Speaker 3>but price then becomes a problem.

0:25:10.961 --> 0:25:14.641
<v Speaker 2>I know, Well you mentioned that, so you get funding

0:25:14.641 --> 0:25:16.481
<v Speaker 2>from a variety of resources. And as you say, you

0:25:16.521 --> 0:25:19.161
<v Speaker 2>mentioned that Daffodil Days about doing so much more for

0:25:19.201 --> 0:25:22.521
<v Speaker 2>the cancer Society, supporting people when their need accommodation and

0:25:22.561 --> 0:25:25.401
<v Speaker 2>to visit centers for cancer treatment and that holistic sort

0:25:25.401 --> 0:25:28.761
<v Speaker 2>of support I guess for cancer suffers in their families.

0:25:29.161 --> 0:25:31.361
<v Speaker 2>By the way, I'm going to keep plugging this if

0:25:31.361 --> 0:25:34.041
<v Speaker 2>you want to text two four four two text the

0:25:34.081 --> 0:25:36.721
<v Speaker 2>word donate and you can click a link and select

0:25:36.761 --> 0:25:41.481
<v Speaker 2>your donation for Daffodil Day, which may be on Friday,

0:25:41.481 --> 0:25:43.481
<v Speaker 2>the thirtieth of August. But you can get stuck into

0:25:43.521 --> 0:25:46.121
<v Speaker 2>it right now. And I've completely forgotten the question I

0:25:46.201 --> 0:25:50.041
<v Speaker 2>was going to ask there. Maybe that's a that's a

0:25:50.081 --> 0:25:52.201
<v Speaker 2>moment for me to take a break and I'll come

0:25:52.201 --> 0:25:53.441
<v Speaker 2>and work out what i was going to ask, because

0:25:53.441 --> 0:25:55.201
<v Speaker 2>I've got a truck load of questions. If you have

0:25:55.281 --> 0:26:00.601
<v Speaker 2>any questions for Professor Sir Bill Denny, he's former director

0:26:00.641 --> 0:26:03.961
<v Speaker 2>of the Auckland Cancer Society Research Center, you can call

0:26:04.121 --> 0:26:07.161
<v Speaker 2>or text now eight hundred eighty ten eighty or text

0:26:07.281 --> 0:26:09.281
<v Speaker 2>nine two niney two and back in a moment. It's

0:26:09.321 --> 0:26:13.761
<v Speaker 2>twenty four minutes to five News talks 'b Yes, and

0:26:13.841 --> 0:26:16.641
<v Speaker 2>did you know that one in six New Zealanders experience

0:26:16.761 --> 0:26:19.361
<v Speaker 2>hearing loss and choosing the right hearing solution for your

0:26:19.361 --> 0:26:22.721
<v Speaker 2>individual needs is important. Your local Triton Hearing team will

0:26:22.761 --> 0:26:25.121
<v Speaker 2>work with you to find the best hearing solution for

0:26:25.161 --> 0:26:29.201
<v Speaker 2>your listening needs, lifestyle and budget. So if you or

0:26:29.201 --> 0:26:31.481
<v Speaker 2>someone close to you as considering hearing aids, The twenty

0:26:31.561 --> 0:26:34.001
<v Speaker 2>twenty four Consumers Guide to Hearing Aids is out now

0:26:34.161 --> 0:26:37.761
<v Speaker 2>and available exclusively from Triton Hearing. It's the only truly

0:26:37.801 --> 0:26:39.881
<v Speaker 2>independent guide in New Zealand, so you know you're getting

0:26:39.881 --> 0:26:42.441
<v Speaker 2>the best advice. Find out about the latest hearing aids

0:26:42.441 --> 0:26:45.921
<v Speaker 2>from top brands. There's information on everything from features and

0:26:46.041 --> 0:26:48.081
<v Speaker 2>styles to a price guard to help you choose the

0:26:48.121 --> 0:26:51.681
<v Speaker 2>right hearing devices for your lifestyle and budget. To order

0:26:51.721 --> 0:26:54.841
<v Speaker 2>your free twenty twenty four Consumers Guide to Hearing Aids,

0:26:55.161 --> 0:26:59.601
<v Speaker 2>simply visit Tritonhearing dot co dot Nz or call on

0:26:59.921 --> 0:27:04.161
<v Speaker 2>eight hundred forty five forty five forty two. That's eight

0:27:04.241 --> 0:27:07.361
<v Speaker 2>hundred four forty five forty two.

0:27:07.761 --> 0:27:10.521
<v Speaker 1>Helping you get on top of your busy life. Tim

0:27:10.521 --> 0:27:13.201
<v Speaker 1>Beveridge on the Weekend Collector News.

0:27:13.041 --> 0:27:15.641
<v Speaker 2>Talk said, be yes and welcome back to the show.

0:27:15.681 --> 0:27:17.681
<v Speaker 2>This is the Health Hub and my guest is a

0:27:17.721 --> 0:27:20.961
<v Speaker 2>special guest, professor Sir Bill Denny. He's former director of

0:27:21.001 --> 0:27:24.281
<v Speaker 2>the Auckland Cancer Society Research Center. And the reason that

0:27:24.281 --> 0:27:26.561
<v Speaker 2>Bill's with me is to have a chat about the

0:27:26.601 --> 0:27:29.081
<v Speaker 2>science and just to help us get a bit more

0:27:29.081 --> 0:27:31.401
<v Speaker 2>of an understanding of their amazing work that our New

0:27:31.481 --> 0:27:35.921
<v Speaker 2>Zealand scientists are doing. And also that the Cancer Society does,

0:27:36.081 --> 0:27:39.601
<v Speaker 2>and that to that end, with Daffodil Day approaching on

0:27:39.641 --> 0:27:42.721
<v Speaker 2>the Friday the thirtieth, I'm going to keep pushing this

0:27:42.801 --> 0:27:46.521
<v Speaker 2>that you text the word donate to two four four two.

0:27:46.681 --> 0:27:48.961
<v Speaker 2>You can click the link and select your donation now.

0:27:48.961 --> 0:27:51.481
<v Speaker 2>And as Bill was saying earlier on that the work

0:27:51.521 --> 0:27:53.761
<v Speaker 2>of the Cancer Society is so important and funding from

0:27:53.801 --> 0:27:56.761
<v Speaker 2>Daffodil Day because it's not just we're not just about

0:27:56.761 --> 0:28:00.441
<v Speaker 2>supporting science, it's about supporting the holistic needs of families

0:28:00.481 --> 0:28:03.561
<v Speaker 2>and the cancer sufferers who have to travel or whatever

0:28:03.881 --> 0:28:06.641
<v Speaker 2>around people who do with that what is still a

0:28:06.721 --> 0:28:11.721
<v Speaker 2>very challenging illness despite the scientific advances. So Bill, a

0:28:11.881 --> 0:28:14.201
<v Speaker 2>quick question for you is such a thing as a

0:28:14.241 --> 0:28:17.721
<v Speaker 2>quick question? I don't know you mentioned that the funding,

0:28:17.801 --> 0:28:19.961
<v Speaker 2>so you know, the funding from that you apply for

0:28:20.041 --> 0:28:23.001
<v Speaker 2>from government and for different funds, but sometimes you get

0:28:23.001 --> 0:28:30.761
<v Speaker 2>funded by pharmaceutical companies. What makes does it? What does

0:28:30.801 --> 0:28:35.041
<v Speaker 2>it mean once a pharmaceutical company funds something, does that

0:28:35.081 --> 0:28:37.841
<v Speaker 2>mean that they take complete ownership of the results of

0:28:37.881 --> 0:28:39.641
<v Speaker 2>that as well? Or how does that all work in

0:28:39.721 --> 0:28:43.681
<v Speaker 2>Because most people's concern is, oh, those pharmaceutical companies are

0:28:43.721 --> 0:28:45.121
<v Speaker 2>going to put the price up in we're never going

0:28:45.121 --> 0:28:47.641
<v Speaker 2>to be afford our treatment. But of course we need

0:28:47.641 --> 0:28:50.201
<v Speaker 2>their money to fund the research too, don't we.

0:28:50.201 --> 0:28:55.841
<v Speaker 3>We do, And it's only the companies that have the

0:28:55.881 --> 0:29:03.161
<v Speaker 3>funding to take drugs through the necessary government mandated processes

0:29:03.241 --> 0:29:06.361
<v Speaker 3>before it can become available to the public. And that,

0:29:06.561 --> 0:29:11.081
<v Speaker 3>you know, for doing the stage three trials for a

0:29:11.121 --> 0:29:14.521
<v Speaker 3>new drug is one hundred million US dollars and so

0:29:14.641 --> 0:29:19.641
<v Speaker 3>that can't be funded by well, the scientific groups.

0:29:20.401 --> 0:29:22.121
<v Speaker 2>Goodness, we get.

0:29:23.401 --> 0:29:27.121
<v Speaker 3>We have had in the past very productive collaborations with

0:29:27.161 --> 0:29:30.161
<v Speaker 3>pharmaceutical companies who've come in to us and said, we're

0:29:30.201 --> 0:29:32.681
<v Speaker 3>interested in the sort of work that we see you've

0:29:32.721 --> 0:29:37.441
<v Speaker 3>been doing from your publications. We have things in the

0:29:37.481 --> 0:29:40.601
<v Speaker 3>same area. Could we do some work together, and then

0:29:40.641 --> 0:29:44.121
<v Speaker 3>we get funded to do that, We build our relationships

0:29:44.121 --> 0:29:47.681
<v Speaker 3>with those companies and it's all positive all round.

0:29:48.161 --> 0:29:48.361
<v Speaker 5>Man.

0:29:48.401 --> 0:29:49.761
<v Speaker 2>That's a lot of money, isn't it.

0:29:49.801 --> 0:29:52.441
<v Speaker 3>But yes, well, I mean we can get a drug

0:29:52.481 --> 0:29:57.121
<v Speaker 3>to phase one perhaps, but phase two, phase three, the

0:29:57.161 --> 0:29:58.401
<v Speaker 3>companies have to do that.

0:29:58.521 --> 0:30:02.401
<v Speaker 2>How much just okay, one hundred million for stage three trials,

0:30:02.121 --> 0:30:03.721
<v Speaker 2>what's it cost for stage four?

0:30:05.561 --> 0:30:11.641
<v Speaker 3>Well? Really, then you're stage three is really the major

0:30:12.881 --> 0:30:16.481
<v Speaker 3>last stage that's required before a drug will get registered. Okay,

0:30:17.161 --> 0:30:20.121
<v Speaker 3>So there are stage four trials when there are really

0:30:20.281 --> 0:30:22.441
<v Speaker 3>their retrospective trials of drugs that.

0:30:22.441 --> 0:30:26.121
<v Speaker 2>Are already okay, right, so stage three is the important one.

0:30:26.321 --> 0:30:26.521
<v Speaker 4>Yes.

0:30:26.841 --> 0:30:34.561
<v Speaker 2>If New Zealand scientists are developing a drug which is

0:30:34.601 --> 0:30:38.481
<v Speaker 2>effective in treating cancer and it's been funded by a

0:30:38.521 --> 0:30:42.881
<v Speaker 2>big pharmaceutical company, does the fact that it's been invented

0:30:42.961 --> 0:30:45.521
<v Speaker 2>or developed by New Zealand technology, does that mean that

0:30:45.561 --> 0:30:49.641
<v Speaker 2>it's more it's ease more easily accessible by New Zealand

0:30:49.641 --> 0:30:51.241
<v Speaker 2>patients or does that have nothing to do with it.

0:30:51.321 --> 0:30:56.121
<v Speaker 3>I don't think it's possible to do that because often

0:30:57.281 --> 0:31:00.321
<v Speaker 3>we will only get involved with a pharmaceutical company and

0:31:00.841 --> 0:31:03.841
<v Speaker 3>at the stages where we can't do any more work,

0:31:04.401 --> 0:31:06.681
<v Speaker 3>we can't the sort of work that's required to do.

0:31:06.761 --> 0:31:08.801
<v Speaker 3>We can't fund one hundred million dollars for a stage

0:31:08.841 --> 0:31:11.321
<v Speaker 3>three trial, so it has to be taken over by

0:31:11.321 --> 0:31:12.321
<v Speaker 3>the companies to do that.

0:31:13.401 --> 0:31:20.401
<v Speaker 2>Is there and what recent technology is there that's allowed

0:31:20.721 --> 0:31:24.081
<v Speaker 2>researchers to be more effective with their research? Is there

0:31:24.801 --> 0:31:27.121
<v Speaker 2>sort of hardware that's made your job easier?

0:31:29.041 --> 0:31:32.521
<v Speaker 3>Yes, The hardware gets better and better each time. There's

0:31:32.601 --> 0:31:37.361
<v Speaker 3>also a much better availability of being able to find

0:31:37.361 --> 0:31:40.441
<v Speaker 3>out what other people are doing through the Internet, and

0:31:40.481 --> 0:31:43.681
<v Speaker 3>so we can collaborate much more easily than we used

0:31:43.721 --> 0:31:46.521
<v Speaker 3>to do. I mean, in my early days, I spent

0:31:47.721 --> 0:31:51.401
<v Speaker 3>hundreds of hours flying to different parts of the world

0:31:51.481 --> 0:31:53.481
<v Speaker 3>to talk with other people, and now it can all

0:31:53.521 --> 0:31:56.881
<v Speaker 3>be done at home, which is much of an advantage.

0:31:56.401 --> 0:31:59.881
<v Speaker 2>Of the Magic Zoom meeting. So you guys could consider. Actually,

0:31:59.921 --> 0:32:02.761
<v Speaker 2>I was just wondering how things would have been interrupted

0:32:02.841 --> 0:32:07.241
<v Speaker 2>during the whole isolation phase of COVID. I guess how

0:32:07.681 --> 0:32:10.961
<v Speaker 2>did what happened in the science community around that time, I.

0:32:10.881 --> 0:32:14.881
<v Speaker 3>Think slowed down quite a bit. You still have to

0:32:14.921 --> 0:32:19.641
<v Speaker 3>work together at some point, side by side. You couldn't

0:32:19.681 --> 0:32:20.041
<v Speaker 3>do that.

0:32:20.481 --> 0:32:22.641
<v Speaker 2>Okay, let's take let's take a call Liz.

0:32:22.681 --> 0:32:30.601
<v Speaker 5>Hello you Hi Dea, Hello dear. Something that I heard

0:32:31.481 --> 0:32:39.721
<v Speaker 5>was that Massy University had was working on some enzymes,

0:32:40.161 --> 0:32:47.441
<v Speaker 5>as I understand it, that will stop cancer metastasizing. Do

0:32:47.521 --> 0:32:47.841
<v Speaker 5>you know?

0:32:48.481 --> 0:32:51.601
<v Speaker 2>Okay, yep, yeah, Sorry, your lines a bit dodgy there, Liz,

0:32:51.601 --> 0:32:53.521
<v Speaker 2>But I think Liz was saying, she said that Massive

0:32:53.561 --> 0:32:57.001
<v Speaker 2>is doing something about stopping research that's on something that

0:32:57.041 --> 0:33:02.681
<v Speaker 2>stops cancers from metastasizing. You've got any inside running on that.

0:33:02.841 --> 0:33:05.401
<v Speaker 3>No, I'm afraid I haven't. I haven't heard of that.

0:33:06.601 --> 0:33:09.721
<v Speaker 3>I don't know of the specific work that you're talking about. Sorry.

0:33:09.881 --> 0:33:13.001
<v Speaker 2>No, hey, the other thing you mentioned when we were

0:33:13.041 --> 0:33:15.441
<v Speaker 2>chatting in the break A couple of things. But you

0:33:15.481 --> 0:33:18.241
<v Speaker 2>guys using the same sort of technology using for cancer,

0:33:18.241 --> 0:33:21.801
<v Speaker 2>you're doing something on tuberculosis. Is that right?

0:33:21.921 --> 0:33:22.121
<v Speaker 4>Yes?

0:33:22.161 --> 0:33:25.321
<v Speaker 3>It is. I mean that was I had a chance

0:33:25.441 --> 0:33:31.361
<v Speaker 3>meeting with the director of the Global Fund for Tuberculosis

0:33:31.401 --> 0:33:34.561
<v Speaker 3>in New York a few years back, two thousand and eight,

0:33:34.721 --> 0:33:39.561
<v Speaker 3>and we got together and he and just decided we

0:33:39.641 --> 0:33:43.641
<v Speaker 3>would Although we were focused and funded to do cancer,

0:33:44.081 --> 0:33:47.361
<v Speaker 3>we have the same technologies we have can apply to

0:33:47.401 --> 0:33:51.721
<v Speaker 3>other diseases. And provided that we got that totally funded

0:33:51.761 --> 0:33:55.321
<v Speaker 3>by them and no one else other cancerciety was happy

0:33:55.361 --> 0:33:56.121
<v Speaker 3>with us doing that.

0:33:56.601 --> 0:33:59.761
<v Speaker 2>So is this a treatment? Is not a prevention, it's

0:33:59.801 --> 0:34:00.241
<v Speaker 2>a treatment.

0:34:00.521 --> 0:34:05.841
<v Speaker 3>This is a treatment. Yeah, I mean the cancer I

0:34:05.881 --> 0:34:11.761
<v Speaker 3>mean tuberculosis has kills normally one hundred, I mean between

0:34:11.801 --> 0:34:14.641
<v Speaker 3>one to two million people of the year every around

0:34:14.641 --> 0:34:19.161
<v Speaker 3>the world. And the treatment for late stage disease, which

0:34:19.201 --> 0:34:21.721
<v Speaker 3>is which is often what it is when it's when

0:34:21.801 --> 0:34:25.801
<v Speaker 3>people present has been very very difficult. Or recently we've

0:34:25.841 --> 0:34:28.801
<v Speaker 3>been working with the Global Alliance for TV it developed

0:34:28.801 --> 0:34:33.441
<v Speaker 3>a drug TBJ eight seven six it's got no better

0:34:33.521 --> 0:34:37.121
<v Speaker 3>name yet, which is now and we're now in clinical

0:34:37.161 --> 0:34:40.001
<v Speaker 3>trials worldwide and it's clearly effective.

0:34:40.281 --> 0:34:40.681
<v Speaker 2>Wow.

0:34:40.721 --> 0:34:45.481
<v Speaker 3>And the cure rates have gone from thirty five percent

0:34:46.081 --> 0:34:48.241
<v Speaker 3>when this is drug is used up to about ninety

0:34:48.241 --> 0:34:48.881
<v Speaker 3>five percent.

0:34:49.121 --> 0:34:51.521
<v Speaker 2>God, that must be I mean, that must be quite

0:34:51.601 --> 0:34:52.441
<v Speaker 2>a thrill when you.

0:34:52.681 --> 0:34:56.281
<v Speaker 3>So that for us, although it's off our major them,

0:34:57.161 --> 0:35:01.401
<v Speaker 3>for the scientists involved, it's a major it's a major thing.

0:35:01.761 --> 0:35:03.041
<v Speaker 3>We are very very proud of it.

0:35:03.081 --> 0:35:05.201
<v Speaker 2>I guess the other thing we were chatting out the

0:35:05.201 --> 0:35:07.561
<v Speaker 2>break is that it's you know, the New Zealanders tend

0:35:07.601 --> 0:35:09.441
<v Speaker 2>to be pretty modest and obviously you're not going to

0:35:09.441 --> 0:35:12.121
<v Speaker 2>talk about your own successes. But now that you've retired,

0:35:12.161 --> 0:35:14.481
<v Speaker 2>you can talk about the people who are still involved

0:35:14.481 --> 0:35:17.401
<v Speaker 2>in cancer research in New Zealand. I mean, what would

0:35:17.441 --> 0:35:20.481
<v Speaker 2>you how? Our scientists are pretty awesome, aren't they.

0:35:21.761 --> 0:35:27.121
<v Speaker 3>It's almost impossible to judge when you're judging yourself. Yeah,

0:35:27.201 --> 0:35:29.561
<v Speaker 3>but I would say the answer that is absolutely correct.

0:35:29.761 --> 0:35:29.961
<v Speaker 2>Yeah.

0:35:30.201 --> 0:35:33.121
<v Speaker 3>I mean we're a very small group. We've delivered seventeen

0:35:33.201 --> 0:35:35.881
<v Speaker 3>new drugs to clinical trials.

0:35:35.641 --> 0:35:39.001
<v Speaker 2>That's pretty I think that's a big deal. Is it fair?

0:35:39.041 --> 0:35:41.801
<v Speaker 2>You might not look like this comparison, but for instance,

0:35:42.161 --> 0:35:46.161
<v Speaker 2>apparently in per capita we're the best Olympic nation in

0:35:46.201 --> 0:35:48.801
<v Speaker 2>the world. Are we sort of pretty awesome when it

0:35:48.801 --> 0:35:51.361
<v Speaker 2>came in that similar respect when it comes to science

0:35:51.641 --> 0:35:54.081
<v Speaker 2>and cancer development treatments.

0:35:54.841 --> 0:35:56.841
<v Speaker 3>I think that's a very hard call to make.

0:35:59.401 --> 0:36:02.281
<v Speaker 2>Well, of course, it's not comparing apples with oranges or

0:36:02.321 --> 0:36:06.161
<v Speaker 2>something apples with apples. I guess quick question here before

0:36:06.161 --> 0:36:11.041
<v Speaker 2>we go to the break again. Somebody's suggested that's suspicious

0:36:11.081 --> 0:36:15.081
<v Speaker 2>that if a study that you're working on gets funded

0:36:15.081 --> 0:36:18.521
<v Speaker 2>by a pharmaceutical company and it doesn't pan out, do

0:36:18.641 --> 0:36:22.201
<v Speaker 2>those results still get published or this person says, if

0:36:22.201 --> 0:36:24.721
<v Speaker 2>the results don't fall in favor of the pharmaceutical company

0:36:24.721 --> 0:36:27.201
<v Speaker 2>funding the study, they don't have to make it available

0:36:27.201 --> 0:36:30.241
<v Speaker 2>to the public, which is implying that some of the

0:36:30.241 --> 0:36:32.401
<v Speaker 2>failures get covered up, or what do we know about that?

0:36:34.001 --> 0:36:37.441
<v Speaker 3>I don't think that's I mean, as far as we're concerned,

0:36:37.721 --> 0:36:45.121
<v Speaker 3>our collaborations with pharmaceutical companies in the later stages of

0:36:45.161 --> 0:36:48.481
<v Speaker 3>the development of a drug have never stopped us from

0:36:48.521 --> 0:36:51.241
<v Speaker 3>being able to publish the results scientifically, which is what

0:36:51.281 --> 0:36:51.841
<v Speaker 3>we need for.

0:36:51.801 --> 0:36:56.561
<v Speaker 2>Our careers exactly. Okay, so that's yes. I think that's

0:36:56.601 --> 0:37:00.161
<v Speaker 2>a good response to our text. Right. We're going to

0:37:00.161 --> 0:37:01.481
<v Speaker 2>be back in just a moment. It's ten to five

0:37:01.521 --> 0:37:03.241
<v Speaker 2>News Talks there be but before we go to the break,

0:37:03.321 --> 0:37:04.481
<v Speaker 2>just before we go to the break, that's a note

0:37:04.521 --> 0:37:06.361
<v Speaker 2>to my producer not to hit the button so quickly.

0:37:06.881 --> 0:37:10.321
<v Speaker 2>You can text the word donate to two four four

0:37:10.401 --> 0:37:13.041
<v Speaker 2>two and you'll get it. You'll get taken to a

0:37:13.081 --> 0:37:15.481
<v Speaker 2>link and you can select your donation because it is

0:37:15.561 --> 0:37:18.721
<v Speaker 2>Daffodil Day on Friday, the thirtieth of August. But the

0:37:18.801 --> 0:37:21.921
<v Speaker 2>donation drive is underway right now in support of the

0:37:21.961 --> 0:37:24.761
<v Speaker 2>Cancer Society, So get into it right now and we'll

0:37:24.761 --> 0:37:26.601
<v Speaker 2>be back in just mo It's ten to five News

0:37:26.641 --> 0:37:41.041
<v Speaker 2>Talks d B. We welcome back to the Weekend Collective.

0:37:41.081 --> 0:37:44.081
<v Speaker 2>This has been a special health hub with Professor Sibil Denny.

0:37:44.121 --> 0:37:46.921
<v Speaker 2>He's a former director of the Auckland Cancer Society Research Center.

0:37:47.201 --> 0:37:49.961
<v Speaker 2>Just chatting about the developments and science and everything. But

0:37:50.041 --> 0:37:52.081
<v Speaker 2>it's all in support of Daffodil Day. So you can

0:37:52.081 --> 0:37:54.001
<v Speaker 2>text donate to two four four two and click a

0:37:54.041 --> 0:37:57.001
<v Speaker 2>link and select your donation amount. A quick text from

0:37:57.001 --> 0:38:00.721
<v Speaker 2>someone saying I have stage four cancel cancer and on

0:38:00.801 --> 0:38:03.241
<v Speaker 2>trial drugs. Unfortunately, I've just tuned and can I re

0:38:03.321 --> 0:38:05.841
<v Speaker 2>listen to this program somewhere? I'd love to be able

0:38:05.881 --> 0:38:07.561
<v Speaker 2>to listen to the full program. And that's a perfect

0:38:07.601 --> 0:38:10.721
<v Speaker 2>question for me, because yes you can. We get the

0:38:10.721 --> 0:38:13.721
<v Speaker 2>pop podcast up and running not long after the show,

0:38:14.081 --> 0:38:16.601
<v Speaker 2>and you just look for the Weekend Collective and this

0:38:16.641 --> 0:38:18.081
<v Speaker 2>will be online. You can also go to the news

0:38:18.081 --> 0:38:21.761
<v Speaker 2>Talk ZB website and hear the fascinating conversation with Bill.

0:38:22.721 --> 0:38:24.681
<v Speaker 2>But there's not much time left Bill, So I'm just

0:38:24.721 --> 0:38:28.601
<v Speaker 2>going to say I think that while it says retired,

0:38:30.801 --> 0:38:34.121
<v Speaker 2>you are technically retired, but what's what are you up to?

0:38:34.641 --> 0:38:35.241
<v Speaker 2>What's retired?

0:38:35.361 --> 0:38:39.161
<v Speaker 3>Look Black, I seem to occupy most of my mornings

0:38:39.881 --> 0:38:44.961
<v Speaker 3>with scientific work. I'm an editor of two major journals,

0:38:45.201 --> 0:38:51.361
<v Speaker 3>and the requests to review papers and make decisions flooded

0:38:51.481 --> 0:38:55.001
<v Speaker 3>each morning, and that really keeps me occupied till lunchtime.

0:38:56.041 --> 0:38:58.161
<v Speaker 3>Then if the weather is decent, I can get out

0:38:58.201 --> 0:39:00.161
<v Speaker 3>in the garden or go for a long walk or something.

0:39:00.201 --> 0:39:02.241
<v Speaker 2>Okay, so you do have a bit more time at

0:39:02.281 --> 0:39:05.561
<v Speaker 2>your dispose. I do, and I appreciate it's because it

0:39:05.601 --> 0:39:08.401
<v Speaker 2>doesn't sound like it's complete. It's partial retirement, really, isn't it.

0:39:08.481 --> 0:39:11.801
<v Speaker 2>If you're you know, you're editing journals and things.

0:39:11.641 --> 0:39:14.161
<v Speaker 3>Yeah, this is true. I mean the still keeps me

0:39:14.281 --> 0:39:17.401
<v Speaker 3>linked and that that's for me is important to do.

0:39:17.481 --> 0:39:18.281
<v Speaker 4>That is it?

0:39:18.801 --> 0:39:21.721
<v Speaker 2>Also? Is it quite fun editing journals and looking at

0:39:21.721 --> 0:39:23.361
<v Speaker 2>papers and the research that's coming out. Is it sort

0:39:23.361 --> 0:39:25.441
<v Speaker 2>of a bit intimidating as well, because you probably have

0:39:25.441 --> 0:39:27.041
<v Speaker 2>to say yes to some and no to others.

0:39:27.641 --> 0:39:29.321
<v Speaker 3>I have to say yes. I have to say yes

0:39:29.441 --> 0:39:32.801
<v Speaker 3>or no depending on what the reviewers think and depending

0:39:32.801 --> 0:39:35.961
<v Speaker 3>on what I think. And yeah, it and sometimes you

0:39:36.041 --> 0:39:40.481
<v Speaker 3>get calls from frustrated authors who have been turned down. Okay,

0:39:41.321 --> 0:39:44.801
<v Speaker 3>but no, it's it's exciting you keep abreast of what's

0:39:44.841 --> 0:39:47.281
<v Speaker 3>going on in the scientific world in your area.

0:39:47.561 --> 0:39:50.121
<v Speaker 2>Yeah, and so you're and you from what you from

0:39:50.121 --> 0:39:51.961
<v Speaker 2>what you've seen and from your career and everything, you're

0:39:52.001 --> 0:39:54.641
<v Speaker 2>excited about where science is heading at the moment with cancer.

0:39:55.001 --> 0:39:58.681
<v Speaker 3>Yes, yes, absolutely, I mean we have a wider range

0:39:58.721 --> 0:40:01.881
<v Speaker 3>of more useful drugs to choose from than we ever

0:40:01.921 --> 0:40:05.201
<v Speaker 3>had before. Of course, there are issues like funding and

0:40:05.321 --> 0:40:08.321
<v Speaker 3>cost of those drugs which have to be balanced down.

0:40:08.481 --> 0:40:11.201
<v Speaker 3>But the science is going very well.

0:40:11.321 --> 0:40:14.961
<v Speaker 2>Excellent, Hey Bill, thanks so much for your time. Time flies,

0:40:15.001 --> 0:40:15.681
<v Speaker 2>isn't it it?

0:40:15.561 --> 0:40:16.321
<v Speaker 3>It really does.

0:40:16.361 --> 0:40:19.081
<v Speaker 2>Yeah, we were thinking it's an hour. It's a long time,

0:40:19.121 --> 0:40:20.401
<v Speaker 2>but it's over in a flash when you're.

0:40:20.321 --> 0:40:22.321
<v Speaker 3>On talking quicker than even in the borough.

0:40:23.561 --> 0:40:27.321
<v Speaker 2>Indeed, Okay, by the way, as I say, I've mentioned it,

0:40:27.321 --> 0:40:30.241
<v Speaker 2>but text four four two the text weird. Donate and

0:40:30.281 --> 0:40:33.481
<v Speaker 2>go from there. Thanks Bill, and we'll be back shortly

0:40:33.521 --> 0:40:35.881
<v Speaker 2>with smart money. Andrew Besquin from harber Asset Management will

0:40:35.881 --> 0:40:36.401
<v Speaker 2>be joining.

0:40:36.281 --> 0:40:41.041
<v Speaker 1>Us for more from the Weekend Collective. Listen live to

0:40:41.161 --> 0:40:44.401
<v Speaker 1>news Talks it'd be weekends from three pm, or follow

0:40:44.481 --> 0:40:46.121
<v Speaker 1>the podcast on iHeartRadio.